Additional Paid-In Capital
Boston Scientific Additional Paid-In Capital increased by 0.4% to $21.51B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.1%, from $21.06B to $21.51B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 1.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A consistent increase is common for growth companies that frequently issue stock-based compensation or raise capital through equity markets.
Detailed definition
This represents the excess amount paid by investors for common shares above their stated par value. It is a critical com...
Peer comparison
This is a standard equity account for all publicly traded corporations, representing the cumulative historical premium paid by investors.
equity_additional_paid_in_capital_common_stockHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.82B | $19.93B | $19.99B | $20.04B | $20.10B | $20.22B | $20.29B | $20.36B | $20.44B | $20.57B | $20.65B | $20.71B | $20.80B | $20.96B | $21.06B | $21.13B | $21.23B | $21.42B | $21.51B |
| QoQ Change | — | +0.6% | +0.3% | +0.3% | +0.3% | +0.6% | +0.3% | +0.3% | +0.4% | +0.6% | +0.4% | +0.3% | +0.4% | +0.8% | +0.4% | +0.3% | +0.5% | +0.9% | +0.4% |
| YoY Change | — | — | — | — | +1.4% | +1.5% | +1.5% | +1.6% | +1.7% | +1.8% | +1.8% | +1.8% | +1.8% | +1.9% | +2.0% | +2.0% | +2.1% | +2.2% | +2.1% |
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Boston Scientific's additional paid-in capital?
- Boston Scientific (BSX) reported additional paid-in capital of $21.51B in Q4 2025.
- How has Boston Scientific's additional paid-in capital changed year-over-year?
- Boston Scientific's additional paid-in capital increased by 2.1% year-over-year, from $21.06B to $21.51B.
- What is the long-term trend for Boston Scientific's additional paid-in capital?
- Over 5 years (2020 to 2025), Boston Scientific's additional paid-in capital has grown at a 1.7% compound annual growth rate (CAGR), from $19.73B to $21.51B.
- What does additional paid-in capital mean?
- The total amount of capital received from shareholders in excess of the nominal par value of the stock.